Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
Boehringer Ingelheim Establishes Cutting-Edge AI and Machine Learning Hub in London to Accelerate Targeted Medicine Discovery
Boehringer Ingelheim has officially launched a new, state-of-the-art Artificial Intelligence (AI) and Machine Learning (ML) center in London’s King’s Cross,…
Read More
US President Signs Executive Order to Expedite Psychedelic Drug Review and Bolster Research
In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
Boehringer Ingelheim and Zai Lab Forge Clinical Collaboration to Pioneer Novel Combination Therapy for Aggressive Lung Cancers
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
Pharma 50: Keytruda Holds Top Brand Slot as Tirzepatide and Semaglutide Dominate at Molecule Level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant transformation in fiscal year 2025, revealing a nuanced shift in leadership despite…
Read More
Cochrane Review Challenges Clinical Significance of Anti-Amyloid Alzheimer’s Drugs, Pharmaceutical Companies Reaffirm Efficacy
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read MoreYOU MAY HAVE MISSED
